Nintedanib is a small-molecule tyrosine kinase inhibitor that targets multiple pathways involved in fibrosis and angiogenesis. It is commonly used in the treatment of idiopathic pulmonary fibrosis (IPF) and certain types of cancer. Understanding its effects at the histological level is crucial for comprehending its therapeutic benefits and potential side effects.